Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:**\n5-[(4-methylphenyl)sulfanyl]-2,4-quinazolinediamine is a synthetic small molecule featuring a quinazoline core with amino groups at the 2 and 4 positions and a sulfanyl group attached to a para-substituted methylphenyl ring. This structure confers potential biological activity relevant to medicinal chemistry. The compound has been studied as an experimental ligand for dihydrofolate reductase (DHFR), including in Candida albicans and other species. Its mechanism of action is presumed to involve inhibition of DHFR—a key enzyme in folate metabolism—suggesting possible antimetabolite or antimicrobial properties. However, it has not been approved for any clinical use or advanced beyond early-stage research[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-[(4-methylphenyl)sulfanyl]-2,4-quinazolinediamine.